Dikoma C. Shungu, PhD

Highlights

1
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2025
DCDikoma C. Shungu
PMID: 40999233PMCID: PMC12603105DOISenior author2 citations

Publications

140

Funding

25 View NIH portfolio on RePORTER ↗

Active

4 grants

Co-I
The effects of iron on oxidative stress and Alzheimer's biomarkers in amyloid-positive and negative elderly normal
National Institute on Aging · 2020–2027
R01AG068398-05
PI
Mechanistic Assessment of N-Acetylcysteine as an Antioxidant Therapy for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Through Dose Response and Treatment Target Engagement
National Institute of Neurological Disorders and Stroke · 2020–2027
R01NS116887-05
Sub-PI
Treatment Strategies for Mitochondrial Disease
U.S. Department of Defense · 2022–2026 · via Columbia University
W81XWH-20-1-0807
KP
New PET/CT System for Human and Non-human Primate Imaging
Office of the Director, NIH · 2023–2026
S10OD034271-01

Completed grants (21)

PI
Service agreement with Neuronasal, Inc. (2025)
Neuronasal · 2025–2025Contract
SA 253159-01
Sub-PI
The Gulf War Illness Clinical Trials and Interventions Consortium (GWICTIC)
U.S. Department of Defense · 2020–2025 · via Nova Southeastern University
W81XWH-18-2-0062
KP
7T Magnetic Resonance Imaging System for Basic, Translational and Clinical Research
Office of the Director, NIH · 2021–2025
S10OD027039-01A1
KP
Major Cyclotron Upgrades and Refurbishment
Office of the Director, NIH · 2021–2023
S10OD030447-01
PI
Biomarkers of Conversion Risk and Treatment Response in Early-Stage Schizophrenia
National Institute of Mental Health · 2017–2023
R01MH110270-05
MPI
Cornell ME/CFS Collaborative Research Center
National Institute of Neurological Disorders and Stroke · 2017–2023 · via Cornell University - Ithaca
U54NS105541-05
PI
Biomarkers and Brain Mechanisms of Gulf War Illness
U.S. Department of Defense · 2015–2022
W81XWH-15-1-0437
KP
Optimized Multi-Metabolite Edited MRS at 3T
National Institute of Biomedical Imaging and Bioengineering · 2021–2022
K99EB028828-02
PI
Service agreement with Neuronasal, Inc.
Neuronasal · 2021–2022Contract
Neuro-214813
Sub-PI
Treatment Strategies for Mitochondrial Disease
U.S. Department of Defense · 2020–2021 · via Columbia University Medical Center_
W81XWH-19-PRMRP-FPA
Sub-PI
Mitochondrial Encephalomyopathies: Approaches to Treatment
Eunice Kennedy Shriver National Institute of Child Health and Human Development · 2014–2020 · via Columbia University
P01HD080642-05
Sub-PI
Neuroinflammation and PVS Deficits in Adolescents
National Institute of Mental Health · 2014–2018 · via Mount Sinai School of Medicine
5 R01 MH10479-04
PI
Specificity and Validity of Oxidative Stress Model of Chronic Fatigue Syndrome
National Institute of Mental Health · 2013–2017
R01MH100005-03
Sub-PI
The Neuroimmunology of Anhedonia
National Institute of Mental Health · 2012–2017 · via New York University School of Medicine (Grossman)
R01MH095807-05
PI
Novel OCD Medication Strategies to Target Brain Mechanisms in Adolescents
National Institute of Mental Health · 2012–2017
R34MH095377-03 EW
PI
N-Acetylcysteine for Neuroprotection in Parkinsons Disease
National Institute on Aging · 2011–2016
R21AG041509-02 EW
PI
The Antidepressant Action of Ketamine: Brain Chemistry
National Institute of Mental Health · 2011–2016
R01MH093637-04 EW
Sub-PI
Mitochondrial Encephalomyopathies and Mental Retardation
Eunice Kennedy Shriver National Institute of Child Health and Human Development · 2011–2016 · via Columbia University· 2 renewals
P01HD032062-20 EW
Sub-PI
Neuropathologic Abnormalities Define A Subgroup of Patients with CFS
National Institute of Neurological Disorders and Stroke · 2011–2015 · via Beth Israel Medical Center
R21NS075653-02EWO
PI
NAC for Treatment of Oxidative Stress in Chronic Fatigue Syndrome
National Institute of Nursing Research · 2012–2015
R21NR013650-02EWO
PI
Novel MRS Neurotechnology for Imaging GABA & Glutamate Function in Schizophrenia
National Institute of Mental Health · 2007–2012
R01MH075895-05EWO

Clinical research

Active

2 studies

PI
A Multiple Ascending Phase 1 Dose Study of N-acetylcysteine in the Treatment of Patients With the m.3243A>G Mutation and Low Brain Glutathione Levels
PHASE1 · Columbia University · OPEN TO ACCRUAL (as of 2023)
Mitochondrial Disease
NCT05241262
PI
Mechanisms of Oxidative Stress During N-Acetyl Cysteine (NAC) Supplementation in Veterans With Gulf War Illness (GWI)
EARLY_PHASE1 · Nova Southeastern University · OPEN TO ACCRUAL (as of 2022)
Gulf War Syndrome
NCT04987775

Completed & closed trials (1)

PI
Mechanistic Assessment of N-Acetylcysteine as an Antioxidant Therapy for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Through Dose Response and Treatment Target Engagement
PHASE2 · Weill Medical College of Cornell University · CLOSED TO ACCRUAL (as of 2026)
Chronic Fatigue Syndrome; Myalgic Encephalomyelitis
NCT04542161